Consistent with tumor cytokine expression, mice treated with cancer therapeutics and B. bre JCM92 exhibited higher IL-2, STAT5 signaling, and IFN-γ response compared to mice treated with oxaliplatin or PD-1 blockade and B. bre Bb03 (Figure 6F and Figure S2). This evidence concerns the gene IL2 and cancer.